PubMed:32178765 / 2546-2739 JSONTXT

Annnotations TAB JSON ListView MergeView

    Inflammaging

    {"project":"Inflammaging","denotations":[{"id":"T17","span":{"begin":0,"end":193},"obj":"Sentence"},{"id":"T17","span":{"begin":0,"end":193},"obj":"Sentence"}],"text":"Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo."}

    yaoziqian_800_3

    {"project":"yaoziqian_800_3","denotations":[{"id":"T17","span":{"begin":71,"end":81},"obj":"CI"},{"id":"T18","span":{"begin":126,"end":136},"obj":"CI"},{"id":"T19","span":{"begin":185,"end":192},"obj":"CI"}],"text":"Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo."}

    Zierdiyeerkenaili_800_3

    {"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T15","span":{"begin":71,"end":81},"obj":"CI"},{"id":"T16","span":{"begin":126,"end":136},"obj":"CI"},{"id":"T24","span":{"begin":185,"end":192},"obj":"CI"}],"text":"Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo."}